Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net profit rose 126.81% to Rs 102.79 crore in the year ended March 2026 as against Rs 45.32 crore during the previous year ended March 2025. Sales rose 17.88% to Rs 769.60 crore in the year ended March 2026 as against Rs 652.89 crore during the previous year ended March 2025.
For the full year,net profit rose 88.98% to Rs 99.31 crore in the year ended March 2026 as against Rs 52.55 crore during the previous year ended March 2025. Sales rose 19.28% to Rs 768.73 crore in the year ended March 2026 as against Rs 644.47 crore during the previous year ended March 2025.
Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.
Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.
Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the Company in Indonesia.
The product is indicated for the treatment of serious infections caused by multi-drug resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infections